| |
Efficacy and safety of lopinavir/ritonavir versus efavirenz-based
antiretroviral therapy in HIV-infected pregnant Ugandan women.
Cohan D, Natureeba P, Koss CA,
et al
AIDS. 2014 Nov 25.
Abstract
Immunological function restoration with Lopinavir/ritonavir
vs Efavirenz containing regimens in HIV infected patients: a randomized
clinical trial.
Torres B, Rallón N, Loncá M, et al
AIDS Res Hum Retroviruses.
2013 Dec 31
Abstract
A comparison of the long-term durability of nevirapine, efavirenz and
lopinavir in routine
clinical practice in Europe: a EuroSIDA study.
Reekie J, Reiss P, Ledergerber B, Sedlacek D, et al
HIV Med.
2010 Aug 31
Abstract |
The relation between treatment outcome and efavirenz, atazanavir or
lopinavir
exposure in the NORTHIV trial of treatment-naïve HIV-1 infected
patients.
Josephson F, Andersson MC, Flamholc L, et al
Eur J Clin Pharmacol.
2009 Dec 5.
Abstract |
Virological and immunological responses to efavirenz or boosted lopinavir as
first-line therapy
for patients with HIV.
Young J, Bucher HC, Guenthard HF, et al
Antivir Ther.
2009;14(6):771-779.
Abstract |
Observational Study to Evaluate Clinical, Immunological, and
Virological Outcomes
After First-Line Highly Active Antiretroviral Therapy With a Regimen
Including
Either Efavirenz or Lopinavir-Ritonavir in Naive Patients in
Clinical Practice.
Pérez-Elías MJ, Moreno A, Casado JL, et al
JIAPAC 2009 Aug 31.
Abstract |
A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy
Followed by Lopinavir-Ritonavir
Monotherapy versus Efavirenz Combination Therapy.
Cameron DW, da Silva BA, Arribas JR, et al
J Infect Dis. 2008 Jun 9.
Abstract
|
First-line efavirenz versus lopinavir-ritonavir-based highly
active antiretroviral therapy
for naive patients.
Manfredi R, Calza L, Chiodo F.
AIDS. 2004 Nov 19;18(17):2331-3.
Abstract |
|
LPV/RTV/ATZ
vs LPV/RTV/3TC 
LPN/r
Adult/Adol Journal Main Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader